Role of long non-coding RNA SNHG1 in occurrence and progression of ovarian carcinoma
Authors: X-T Yang
K-F Ye
J-M Gao
X-M Wu
J Ge
F Wang
Journal: European review for medical and pharmacological sciences (2018)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: lncRNA SNHG1; ovarian carcinoma; proliferation; apoptosis; invasion
Affiliations: Department of Gynecology, The First People's Hospital of Yunnan Province, Kunming, China. .

Abstract:  Objective: To investigate the expression of human long non-coding ribonucleic acid (lncRNA) small nucleolar RNA host gene 1 (SNHG1) in epithelial ovarian carcinoma tissues and its effects on the in vitro proliferation, apoptosis, invasion and metastasis of ovarian carcinoma cells, and to investigate its possible mechanism. Patients and methods: The expressions of SNHG1 in 20 pairs of epithelial ovarian carcinoma tissues and para-carcinoma normal tissues were detected by Real-time fluorescence quantitative polymerase chain reaction (qRT-PCR). The expressions of SNHG1 in normal ovarian epithelial cells (IOSE25) and ovarian carcinoma cells (CAOV-3, SKOV-3, ES2 and A2780) were further detected. The knockdown efficiency of SNHG1 small interfering RNA (siRNA) in SKOV-3 cells was detected via qRT-PCR. Moreover, the effects of SNHG1 knockdown on proliferation, migration and apoptosis of SKOV-3 cells were detected by cell counting kit 8 (CCK8) proliferation assay, clone formation assay, transwell migration assay and flow cytometry. Finally, the expressions of apoptosis-related proteins, epithelial-mesenchymal transition (EMT)-related proteins and matrix metalloproteinases (MMPs) in control group and interference group were detected by Western blotting. Results: The expression level of lncRNA SNHG1 in ovarian carcinoma tissues was significantly higher than that in para-carcinoma normal tissues. After lncRNA SNHG1 knockdown in SKOV-3 cells, the cell proliferation and clone formation abilities were significantly inhibited. The apoptosis assay proved that inhibiting lncRNA SNHG1 could promote the apoptosis of SKOV-3 cells. Besides, Western blotting revealed that the expressions of pro-apoptotic proteins in interference group were significantly upregulated compared with those in control group. Wound-healing assay and transwell migration assay showed that the down-regulation of lncRNA SNHG1 could inhibit the invasion and metastasis of SKOV-3 cells, whose mechanism was related to the inhibition of EMT process and down-regulation of expressions of MMPs. Conclusions: LncRNA SNHG1 is highly expressed in ovarian carcinoma, which can promote the growth, invasion and metastasis of ovarian carcinoma cells. The down-regulation of SNHG1 can inhibit the proliferation, invasion and metastasis of SKOV-3 cells. Inhibiting the expression of SNHG1 may be a potentially effective means of treating ovarian carcinoma. 

Retracted: No

PubPeer comments:
 *[right]* Fig 2E.  The apoptosis related proteins levels were determined by Western blotting in SKOV-3 cells transfected with si-SNHG1 or si-NC . *[left]* Fig 2E from [Lin et al (2018)] .  The proteins levels of BAX, Bcl-2, cleaved-caspase9 and PARP were determined by Western blotting in si-SNHG1 transfected HEp-2 cells. Unexpectedly similar BAX band. ![file] , 
 *[left]* Fig 3A,  Knockdown of SNHG1 inhibits SKOV-3 cells migration and invasion in vitro . The panels were taken from *[below]* Fig 3A of  Low Molecular Weight Hyaluronan Induces Lymphangiogenesis through LYVE-1-Mediated Signaling Pathways ([Wu et al 2014] ), after a 180-deg flip to make them original work. ![file] , 
 *[above]* Fig 2B. Obtained from *[below]* Fig 2A of  Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells ([Peng et al 2014] ). ![file] , 
 *[above]* Fig 2C. The source is *[below]* Fig 1 of  Effect of ECRG2 in combination with cisplatin on the proliferation and apoptosis of EC9706 cells ([Song et al 2014] ). ![file] , 
 Retraction, September 2022: https: www.europeanreview.org article 29614  he article u201cRole of long non-coding RNA SNHG1 in occurrence and progression of ovarian carcinoma, by J. Ge, X.-M. Wu, X.-T. Yang, J.-M. Gao, F. Wang, K.-F. Ye, published in Eur Rev Med Pharmacol Sci 2018; 22 (2): 329-335u2013DOI: 10.26355 eurrev_201801_14176u2013PMID: 29424921u201d has been retracted by the authors. After publication, the article was questioned on PubPeer. Concerns were expressed about Figures 2 and 3, raising doubts about the originality of data and the reliability of the published results. ,